MOLOGEN AG
MOLOGEN AG: First approvals for phase III IMPALA colorectal cancer study
MOLOGEN AG / Key word(s): Study MOLOGEN AG: First approvals for phase III IMPALA colorectal cancer study Berlin, August 4, 2014 – MOLOGEN AG, a biotechnology company focused on cancer immunotherapy, has received first approvals from the countries participating in the phase III pivotal trial IMPALA. The company expects the first patient in the study (FPI) in the third quarter 2014. The trial is investigating the efficacy of the immunotherapy MGN1703 to improve overall survival (OS) in patients with metastatic colorectal carcinoma. MOLOGEN initiated the approval process for the IMPALA trial in the second quarter of 2014. Study applications were submitted to the corresponding authorities in eight European countries, including the five major pharma markets. As expected, first approvals have been obtained in the meantime. The company assumes to start patient recruitment in the course of the third quarter 2014, as planned. IMPALA is a randomized, international, multicenter and controlled phase III trial. Patients to be enrolled must have achieved a response during their first line treatment of metastatic colorectal cancer. The study aim is to prove that a switch maintenance therapy with the cancer immunotherapy MGN1703 leads to an increased overall survival. The study will include approximately 540 patients from more than 100 European centers. Dr. Alfredo Zurlo, Chief Medical Officer of MOLOGEN AG, commented, “The clinical development program of MGN1703 is progressing as planned. We are confident to enroll the first patient in the IMPALA trial in the next few weeks.” According to the World Health Organization (WHO), colorectal cancer is among the top three cancer indications worldwide and there are approx. 1.4 million newly diagnosed colorectal cancer cases per year. About IMPALA The primary endpoint is overall survival and secondary study endpoints include progression-free survival from start of induction therapy, toxicity and safety, and Quality of Life (QoL). The coordinating study investigators are Prof. David Cunningham, MD, Department of Medicine and Director of Clinical Research, Royal Marsden Hospital in London, and Prof. Dirk Arnold, head of Klinik für Tumorbiologie Freiburg at the Albert Ludwigs University in Freiburg. About MGN1703 About MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). Second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. MOLOGEN AG PRESS SERVICE: INVESTOR RELATIONS: Note about risk for future predictions
04.08.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | info@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart | |
End of News | DGAP News-Service |
280531 04.08.2014 |